In this article (Clin Cancer Res 2012;18:2326–35), which was published in the April 15, 2012, issue of Clinical Cancer Research (1), there were several errors in the Disclosure of Potential Conflicts of Interest section. Dr. Hong is not an employee of GlaxoSmithKline, nor does he hold stock or ownership in the company. The author regrets these errors.

1.
Hong
DS
,
Vence
L
,
Falchook
G
,
Radvanyi
LG
,
Liu
C
,
Goodman
V
, et al
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency
.
Clin Cancer Res
2012
;
18
:
2326
35
.